In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 3, 2006, Pages 525-528

  Zhang, Y John ^a   Wang, Zhaolin ^a   Sprous, Dennis ^a   Nabioullin, Roustem ^a  

^a Cytrx Laboratories   (United States)

Author keywords

Enzyme inhibitor design; Virtual screening

Indexed keywords

ENZYME INHIBITOR; MALATE DEHYDROGENASE (DECARBOXYLATING); PIPERAZINE DERIVATIVE; SUCCINIMIDE DERIVATIVE;

ARTICLE; COMPUTER MODEL; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY;

BINDING SITES; COMBINATORIAL CHEMISTRY TECHNIQUES; CYTOSOL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MALATE DEHYDROGENASE; NADP; PIPERAZINES; PROTEIN CONFORMATION; PYRROLIDINES; PYRROLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29544450754     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.10.065     Document Type: Article

References (20)

1. R. Frenkel Curr. Topics Cell Regul. 9 1975 157
2. R.Y. Hsu Mol. Cell. Biochem. 43 1982 3
3. A.G. Goodridge, S.A. Klautky, D.A. Fantozzi, R.A. Baillie, D.W. Hodnett, W. Chen, D.C. Thurmond, G. Xu, and C. Roncero Prog. Nucleic Acid Res. Mol. Biol. 52 1996 89
4. R.W. Moreadith, and A.L. Lehninger J. Biol. Chem. 259 1984 6215
5. Y. Xu, G. Bhargava, H. Wu, and G. Loeber Structure 7 1999 877
6. G.-G. Chang, and L. Tong Biochemistry 44 2003 12721
7. M.G. Rossman, and A. Liljas J. Mol. Biol. 85 1974 177
8. M. Buehner, G.C. Ford, D. Moras, K.W. Olsen, and M.G. Rossman Proc. Natl. Acad. Sci. U.S.A. 70 1973 3052
9. R.Y. Hsu, and H.A. Lardy J. Biol. Chem. 242 1967 520
10. SYBYL. Tripos Inc. St. Louis MO, USA.
11. R.D. Clark J. Chem. Inf. Comput. Sci. 37 1997 1181
12. M. Rarey, B. Kramer, T. Lengauer, and G. Klebe J. Mol. Biol 251 1995 470
13. R.D. Clark, A. Strizhev, J.M. Leonard, J.F. Blake, and J.B. Matthew J. Mol. Mod. Graph 20 2002 281
14. +.
15. For detailed therapeutic information of 2,5-dioxopyrrolidine-based drugs, please consult Merck Index and MDL's MDDR database.
16. P. D'Andrea, M. Porcelloni, A. Madami, R. Patacchini, M. Altamura, and D. Fattori Bioorg. Med. Chem. Lett. 15 2005 585
17. D.C. rees, M. Congreve, C.W. Murray, and R. Carr Nat. Rev. Drug Disc. 3 2004 660
18. A.C. Pierce, G. Rao, and G.W. Bemis J. Med. Chem. 47 2004 2768
19. D.A. Erlanson, R.S. McDowell, and T. O'Brien J. Med. Chem. 47 2004 3463
20. 2, and appropriate amounts of enzyme was pre-incubated with compounds for 45 min at room temperature. Then reactions were initiated by addition of 124 μ M NADP. After 30 min at room temperature, the reaction was stopped with 0.5 M EDTA. Fifty microliters of 3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) 2H-tetrazolium/phenazinemethosulfate (MTS/PMS) was added, and absorbance was measured at 492 nm.